Medicenna Therapeutics Corp (TSX:MDNA)

C$ 2.36 0.02 (0.85%) Market Cap: 176.48 Mil Enterprise Value: 154.72 Mil PE Ratio: 0 PB Ratio: 8.47 GF Score: 42/100

Medicenna Therapeutics Corp MDNA11 Clinical Update Call Transcript
Aug 09, 2023
Medicenna Therapeutics Corp at Bloom Burton & Co Healthcare Investor Conference Transcript
Apr 25, 2023
Medicenna Therapeutics Corp at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Medicenna Therapeutics Corp at Guggenheim Healthcare Talks Oncology Day Transcript
Feb 09, 2023
Q3 2023 Medicenna Therapeutics Corp Earnings Call Transcript
Feb 07, 2023

C$1 (-0.99%)

Earnings
Q2 2023 Medicenna Therapeutics Corp Earnings Call Transcript
Nov 04, 2022

C$0.88 (-4.35%)

Earnings
Medicenna Therapeutics Corp Annual Shareholders Meeting Transcript
Sep 21, 2022
Q1 2023 Medicenna Therapeutics Corp Earnings Call Transcript
Aug 15, 2022

C$1.27 (-6.62%)

Earnings
Q4 2022 Medicenna Therapeutics Corp Earnings Call Transcript
Jun 22, 2022

C$1.27 (+14.41%)

Earnings
Medicenna Therapeutics Corp at Bloom Burton & Co. Healthcare Investor Conference Transcript
May 02, 2022
Q3 2022 Medicenna Therapeutics Corp Earnings Call Transcript
Feb 09, 2022

C$2.31 (-2.53%)

Earnings
Q2 2022 Medicenna Therapeutics Corp Earnings Call Transcript
Nov 12, 2021

C$2.56

Earnings
Medicenna Therapeutics Corp Annual Shareholders Meeting Transcript
Sep 23, 2021
Medicenna Therapeutics Corp at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 20, 2021
Q1 2022 Medicenna Therapeutics Corp Earnings Call Transcript
Aug 13, 2021

C$2.61 (-4.74%)

Earnings
Medicenna Therapeutics Corp MDNA11 Program Update Call Transcript
Jul 27, 2021
Q4 2021 Medicenna Therapeutics Corp Earnings Call Transcript
May 28, 2021

C$4.7 (-0.42%)

Earnings
Medicenna Therapeutics Corp at Cowen Healthcare Conference (Virtual) Transcript
Mar 02, 2021
Medicenna Therapeutics Corp. - Special Call Transcript
Dec 11, 2020
Medicenna Therapeutics Corp. - Special Call Transcript
Mar 25, 2020
Medicenna Therapeutics Corp to Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study Results Transcript
Nov 25, 2019

Medicenna Therapeutics Corp at Cowen Healthcare Conference (Virtual) Transcript

Mar 02, 2021 / 07:10PM GMT

Release Date Price: C$5.04 (-1.75%)

Transcript

Laura Christianson

Cowen and Company, LLC, Research Division - Research Associate

Hello. Welcome to our fireside chat with Medicenna Therapeutics. I have with me President and CEO, Fahar Merchant. Medicenna is developing Superkines as immunotherapy for cancer. Their lead program is in GBM, and then IL-2 program is another key focus.

We'll start with an overview of the company followed by Q&A. So feel free to put any questions you have on the online portal, and we'll get to them at the end of the presentation. And with that, I will hand it over to Fahar.

Fahar Merchant

Medicenna Therapeutics Corp. - Founder, Chairman, CEO & President

Well, thank you very much. I'm glad that you could make it to this presentation and fireside chat. Just to let you know, I'll be making forward-looking statements, so I encourage you to look at our regulatory filings for these risk factors, et cetera.

So the company is a Canadian company. We are based out of Toronto but listed both on NASDAQ as well as TSX. The company's focus, really, as was mentioned,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.